Floatz logo

TAMOXIFEN

Male Breast Cancer

Jose Pablo LeoneSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
University of California, Irvine
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →